Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-S: Andexanet alfa in patients on factor Xa inhibitors requiring urgent surgery
MOH_2021-03-20_009851Phase 3Not yet recruiting
- Sponsor
- Portola Pharmaceuticals
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of andexanet alfa, sponsored by Portola Pharmaceuticals. Primary endpoint: Hemostatic efficacy after treatment with andexanet alfa. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
andexanet alfa
Beyond the preview
Go deeper on MOH_2021-03-20_009851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-20_009851.